Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pazopanib Hydrochloride

FDA-approved product (tablet, oral), marketed as Pazopanib Hydrochloride, Votrient.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pazopanib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Collecting duct carcinoma
  • Papillary renal cell carcinoma
  • Renal cell carcinoma
  • Sarcoma
  • Soft tissue sarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pazopanib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pazopanib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

    NCT04199026 · start 2025-02-25

    Registered record
    Registry ID
    NCT04199026
    Conditions
    Metastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma
    Interventions
    Doxorubicin; Doxorubicin Hydrochloride; Drug Delivery Microdevice; Everolimus; Ganitumab; Ifosfamide; Irinotecan; Pazopanib; Polyethylene Glycol; Temozolomide; Temsirolimus; Therapeutic Conventional Surgery; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-02-25
    Completion
    2028-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Sarcoma; Recurrent Sarcoma; Resectable Sarcoma
    InterventionDoxorubicin; Doxorubicin Hydrochloride; Drug Delivery Microdevice; Everolimus +9 more
    PhaseNot applicable
    Registry statusRecruiting

  • Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

    NCT03660930 · start 2019-04-01

    Registered record
    Registry ID
    NCT03660930
    Conditions
    Advanced Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma
    Interventions
    Sirolimus Albumin-bound Nanoparticles; Pazopanib hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-04-01
    Completion
    2024-07-31
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma
    InterventionSirolimus Albumin-bound Nanoparticles; Pazopanib hydrochloride
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

    NCT03334409 · start 2018-02-16

    Registered record
    Registry ID
    NCT03334409
    Conditions
    Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7; Unresectable Renal Cell Carcinoma
    Interventions
    Ascorbic Acid; Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-16
    Completion
    2021-03-13
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7 +1 more
    InterventionAscorbic Acid; Pazopanib Hydrochloride
    PhasePhase 2
    Registry statusTerminated

  • Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

    NCT02601209 · start 2015-11-30

    Registered record
    Registry ID
    NCT02601209
    Conditions
    High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Metastatic Unresectable Sarcoma; Myxofibrosarcoma; Recurrent Leiomyosarcoma; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Synovial Sarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8; Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8; Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma
    Interventions
    Pazopanib; Pazopanib Hydrochloride; Sapanisertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-11-30
    Completion
    2022-07-11
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor; Metastatic Synovial Sarcoma +15 more
    InterventionPazopanib; Pazopanib Hydrochloride; Sapanisertib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

    NCT02551718 · start 2015-09-11

    Registered record
    Registry ID
    NCT02551718
    Conditions
    Recurrent Acute Leukemia of Ambiguous Lineage; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Acute Leukemia of Ambiguous Lineage
    Interventions
    Chemosensitivity Assay; Cytology Specimen Collection Procedure; Gene Expression Analysis; Genetic Variation Analysis; In Vitro Sensitivity-Directed Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-09-11
    Completion
    2021-05-13
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Acute Leukemia of Ambiguous Lineage; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia +2 more
    InterventionChemosensitivity Assay; Cytology Specimen Collection Procedure; Gene Expression Analysis; Genetic Variation Analysis +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

    NCT02357810 · start 2015-03-21

    Registered record
    Registry ID
    NCT02357810
    Conditions
    Adult Liposarcoma; Metastatic Liposarcoma; Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Liposarcoma; Recurrent Osteosarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    Pazopanib Hydrochloride; Oral Topotecan Hydrochloride; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03-21
    Completion
    2021-10-12
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Liposarcoma; Metastatic Liposarcoma; Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma +3 more
    InterventionPazopanib Hydrochloride; Oral Topotecan Hydrochloride; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

    NCT02180867 · start 2014-08-12

    Registered record
    Registry ID
    NCT02180867
    Conditions
    Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Fibrosarcoma; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Liver Embryonal Sarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Skin Granular Cell Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Skin Glomus Tumor; Stage IB Soft Tissue Sarcoma AJCC v7; Stage IIB Soft Tissue Sarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Synovial Sarcoma; Undi
    Interventions
    Doxorubicin; Doxorubicin Hydrochloride; Ifosfamide; Pazopanib; Pazopanib Hydrochloride; Radiation Therapy; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-08-12
    Completion
    2026-03-31
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue +32 more
    InterventionDoxorubicin; Doxorubicin Hydrochloride; Ifosfamide; Pazopanib +3 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

    NCT01841736 · start 2013-09-20

    Registered record
    Registry ID
    NCT01841736
    Conditions
    Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Neuroendocrine Tumor; Midgut Neuroendocrine Tumor G1; Neuroendocrine Tumor G2; Recurrent Digestive System Neuroendocrine Tumor G1; Regional Digestive System Neuroendocrine Tumor G1
    Interventions
    Biospecimen Collection; Computed Tomography; Echocardiography Test; Laboratory Biomarker Analysis; Magnetic Resonance Imaging; Multigated Acquisition Scan; Pazopanib Hydrochloride; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-09-20
    Completion
    2026-09-10
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionForegut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Neuroendocrine Tumor +4 more
    InterventionBiospecimen Collection; Computed Tomography; Echocardiography Test; Laboratory Biomarker Analysis +6 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

    NCT01767636 · start 2013-05-16

    Registered record
    Registry ID
    NCT01767636
    Conditions
    Carcinoma of the Collecting Ducts of Bellini; Chromophobe Renal Cell Carcinoma; Kidney Medullary Carcinoma; Kidney Oncocytoma; Metastatic Renal Cell Cancer; Papillary Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer
    Interventions
    Pazopanib Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-05-16
    Completion
    2021-01-20
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma of the Collecting Ducts of Bellini; Chromophobe Renal Cell Carcinoma; Kidney Medullary Carcinoma; Kidney Oncocytoma +5 more
    InterventionPazopanib Hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

    NCT01684397 · start 2012-11-21

    Registered record
    Registry ID
    NCT01684397
    Conditions
    Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer
    Interventions
    Bevacizumab; Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2012-11-21
    Completion
    2026-08-20
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer
    InterventionBevacizumab; Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

    NCT01713972 · start 2012-11-19

    Registered record
    Registry ID
    NCT01713972
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    dabrafenib; pazopanib hydrochloride; Correlative studies
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11-19
    Completion
    2018-12-26
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventiondabrafenib; pazopanib hydrochloride; Correlative studies
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

    NCT01575548 · start 2012-08-08

    Registered record
    Registry ID
    NCT01575548
    Conditions
    Clear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Computed Tomography; Magnetic Resonance Imaging; Pazopanib Hydrochloride; Placebo Administration; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2012-08-08
    Completion
    2027-02-20
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v7
    InterventionComputed Tomography; Magnetic Resonance Imaging; Pazopanib Hydrochloride; Placebo Administration +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

    NCT01664182 · start 2012-08-01

    Registered record
    Registry ID
    NCT01664182
    Conditions
    Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Bevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate; Trebananib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2020-12-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionBevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate +1 more
    PhasePhase 2
    Registry statusCompleted

  • Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

    NCT01402271 · start 2012-07

    Registered record
    Registry ID
    NCT01402271
    Conditions
    Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
    Interventions
    carboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2020-07-13
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
    Interventioncarboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

    NCT01599832 · start 2012-06

    Registered record
    Registry ID
    NCT01599832
    Conditions
    Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
    Interventions
    pazopanib hydrochloride; laboratory biomarker analysis; dynamic contrast-enhanced magnetic resonance imaging; pharmacogenomic studies
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2015-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
    Interventionpazopanib hydrochloride; laboratory biomarker analysis; dynamic contrast-enhanced magnetic resonance imaging; pharmacogenomic studies
    PhaseNot applicable
    Registry statusTerminated